Napp: Nyxoid described as “a new option” on website beyond 12 months (AUTH/3306/2/20)

📊

Key facts

⌄

Case number	AUTH/3306/2/20
Company	Napp Pharmaceuticals Limited
Product	Nyxoid (intranasal naloxone spray)
Issue	Use of the word “new” (“a new option”) beyond 12 months of general availability
Material	Corporate website page (napp.co.uk/overdose-therapy), downloaded 6 February 2020
Complainant	Concerned UK health professional
Applicable Code year	2019
Breach clauses	Clause 7.11
Panel decision	Breach of Clause 7.11 ruled
Company response	Apologised; said it was an oversight; removed the section and updated the page; acknowledged breach
Complaint received	6 February 2020
Case completed	9 April 2020
Appeal	No appeal
Sanctions	Undertaking received

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

📋

⌄

A UK health professional complained about a Napp corporate webpage (downloaded 6 February 2020) describing Nyxoid (intranasal naloxone spray) as “a new option” for treating overdose.
The complainant said Nyxoid had been on the market for more than 12 months.
The PMCPA asked Napp to consider Clause 7.11 (use of the word “new”).
Napp said the page was general product information on its corporate website and apologised, stating it was an oversight.
After the complaint, Napp removed the relevant section and made changes to align with Clause 7.11.

⚖️

⌄

Breach ruled: Yes.
The Panel ruled that describing Nyxoid as “a new option” on 6 February 2020 breached the Code because the medicine had been generally available for more than 12 months.
Napp acknowledged the breach.
No appeal.

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access